Literature DB >> 32769037

Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members.

Michael J Diaz1, Boris I Chobrutskiy1, Saif Zaman1, George Blanck2.   

Abstract

Immunogenomics studies of colon cancer have lagged behind other cancer types, such as melanoma and lung cancer, potentially limiting immunotherapy approaches to colon cancer, also less common than in the cases of melanoma and lung cancer. Here we applied an extensively benchmarked algorithm for retrieving immune receptor recombination sequencing reads from colon cancer exomes available via the cancer genome atlas. Assessment of the complementarity determining region-3 chemical features represented by the reads revealed associations of distinct chemical features with better or worse survival rates, for both T-cell and B-cell receptor, recombination reads. A follow up assessment of immune gene expression correlations with the recovery of the recombination reads revealed a consistent association of high level expression of BTN gene family members and better survival rates. Overall, these approaches provide several striking consistencies connecting immunogenomics features with colon cancer survival rates, potentially providing a basis for guiding immuno-therapy applications.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  BTN gene family; CDR3 chemistry; Colon cancer; T- and B-cell receptor; immune gene expression

Mesh:

Substances:

Year:  2020        PMID: 32769037     DOI: 10.1016/j.ctarc.2020.100196

Source DB:  PubMed          Journal:  Cancer Treat Res Commun        ISSN: 2468-2942


  1 in total

1.  Immune receptor CDR3 chemical features that preserve sequence information are highly efficient in reflecting survival distinctions: A pan-cancer analysis.

Authors:  Brooke E Mcbreairty; Boris I Chobrutskiy; Andrea Chobrutskiy; Etienne C Gozlan; Michael J Diaz; George Blanck
Journal:  Biomed Rep       Date:  2022-06-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.